80 related articles for article (PubMed ID: 16406016)
1. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.
Pardanani A; Ketterling RP; Li CY; Patnaik MM; Wolanskyj AP; Elliott MA; Camoriano JK; Butterfield JH; Dewald GW; Tefferi A
Leuk Res; 2006 Aug; 30(8):965-70. PubMed ID: 16406016
[TBL] [Abstract][Full Text] [Related]
2. A challenging diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement.
Coltro G; Santi R
Blood; 2023 May; 141(20):2541. PubMed ID: 37200055
[No Abstract] [Full Text] [Related]
3. Osteolytic lesion as initial presentation in FIP1L1-PDGFRA-rearranged myeloid/lymphoid neoplasm with eosinophilia: a case report.
Lv Y; Yao X; Ling Q; Suo S; Wang J; Zhao S; Gao X; Tong H; Jin J; Zhang X; Yu W
Ann Hematol; 2024 Jan; 103(1):357-360. PubMed ID: 37777636
[No Abstract] [Full Text] [Related]
4. False-Negative Testing for FIP1L1::PDGFRA by Fluorescence in situ Hybridization Is a Frequent Cause of Diagnostic Delay.
Pongdee T; Berry A; Wetzler L; Sun X; Thumm L; Yoon P; Kuang FL; Makiya M; Constantine G; Khoury P; Rheinbay E; Lane AA; Maric I; Klion AD
Acta Haematol; 2023; 146(4):316-321. PubMed ID: 37285821
[TBL] [Abstract][Full Text] [Related]
5. FIP1L1::PDGFRA fusion driving three synchronous haematological malignancies.
Krigstein M; Menzies A; Fay K; Lukeis R; Cheung K; Parker A
Pathology; 2023 Dec; 55(7):1040-1044. PubMed ID: 37563028
[No Abstract] [Full Text] [Related]
6. Successful Long-Term Control of the Syndrome of Episodic Angioedema With Eosinophilia (Gleich Syndrome) With Low-Dose Imatinib Mesylate and Prednisone.
Butterfield JH
J Investig Med High Impact Case Rep; 2021; 9():2324709620987691. PubMed ID: 33459036
[TBL] [Abstract][Full Text] [Related]
7. Novel
Alsouqi A; Kleinberger J; Werner TS; Awan R; Chopra S; Rea B; Aggarwal N; Yatsenko SA; Farah R; Bailey NG
Haematologica; 2023 Nov; 108(11):3181-3185. PubMed ID: 37102594
[No Abstract] [Full Text] [Related]
8. The challenge of diagnosing and classifying eosinophilia and eosinophil disorders: A review.
Szymczyk A; Jaworski J; Podhorecka M
Cent Eur J Immunol; 2024; 49(1):60-69. PubMed ID: 38812609
[TBL] [Abstract][Full Text] [Related]
9. Marked eosinophilic atypia in a patient with asthma and myeloid/lymphoid neoplasm with FIP1L1::PDGFRA fusion.
Deb PQ; Li L
Br J Haematol; 2024 Apr; ():. PubMed ID: 38685615
[No Abstract] [Full Text] [Related]
10. A myeloid neoplasm with FIP1L1-PDGFRA presenting as acute myeloid leukemia.
Cadenas FL; Bua BR; Campelo MD; Rieu JB; Bain BJ
Am J Hematol; 2020 Oct; 95(10):1214-1215. PubMed ID: 32311158
[No Abstract] [Full Text] [Related]
11. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Marabelle A; Fakih M; Lopez J; Shah M; Shapira-Frommer R; Nakagawa K; Chung HC; Kindler HL; Lopez-Martin JA; Miller WH; Italiano A; Kao S; Piha-Paul SA; Delord JP; McWilliams RR; Fabrizio DA; Aurora-Garg D; Xu L; Jin F; Norwood K; Bang YJ
Lancet Oncol; 2020 Oct; 21(10):1353-1365. PubMed ID: 32919526
[TBL] [Abstract][Full Text] [Related]
12. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2019 Oct; 94(10):1149-1167. PubMed ID: 31423623
[TBL] [Abstract][Full Text] [Related]
13. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.
Valent P; Klion AD; Horny HP; Roufosse F; Gotlib J; Weller PF; Hellmann A; Metzgeroth G; Leiferman KM; Arock M; Butterfield JH; Sperr WR; Sotlar K; Vandenberghe P; Haferlach T; Simon HU; Reiter A; Gleich GJ
J Allergy Clin Immunol; 2012 Sep; 130(3):607-612.e9. PubMed ID: 22460074
[TBL] [Abstract][Full Text] [Related]
14. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.
Patnaik MM; Tefferi A
Am J Hematol; 2024 Jun; 99(6):1142-1165. PubMed ID: 38450850
[TBL] [Abstract][Full Text] [Related]
15. Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms.
Gotlib J
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):34-46. PubMed ID: 36485158
[TBL] [Abstract][Full Text] [Related]
16. How I diagnose and treat chronic myelomonocytic leukemia.
Patnaik MM
Haematologica; 2022 Jul; 107(7):1503-1517. PubMed ID: 35236051
[TBL] [Abstract][Full Text] [Related]
17. Paratrabecular myelofibrosis and occult mastocytosis are strong morphological clues to suspect
Sreedharanunni S; Sachdeva MUS; Sharma S; Rana S; Sandal R; Kumar N; Sharma P; Naseem S; Ahluwalia J; Das R; Malhotra P; Varma N
Indian J Hematol Blood Transfus; 2020 Apr; 36(2):384-389. PubMed ID: 32425395
[TBL] [Abstract][Full Text] [Related]
18. [Differential diagnosis of hypereosinophilia].
Henes JC; Wirths S; Hellmich B
Z Rheumatol; 2019 May; 78(4):313-321. PubMed ID: 30635705
[TBL] [Abstract][Full Text] [Related]
19. Imatinib-Associated Tumor Lysis Syndrome in a Patient With Myeloid Neoplasm With Eosinophilia and PDGFRA Rearrangement: A Case Report and Review of the Literature.
Socola F; Hawes V; Lobo RH; Sasapu A
J Glob Oncol; 2018 Sep; 4():1-4. PubMed ID: 30241197
[No Abstract] [Full Text] [Related]
20. Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.
Patnaik MM; Tefferi A
Am J Hematol; 2018 Jun; 93(6):824-840. PubMed ID: 29878489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
